Abbott Laboratories v. Frank D. Young, Dr., Commissioner, Food and Drug Administration
Court of Appeals for the D.C. Circuit
1Opinion of the Court
Opinion for the Court filed by Circuit Judge SILBERMAN.
Dissenting Opinion filed by Circuit Judge EDWARDS.
SILBERMAN, Circuit Judge:
This is an unusual case in which both the appellant and the government present us with unreasonable interpretations of a statute we think ambiguous. We therefore direct the district court to remand to the agency for reconsideration.
I
In 1984, Congress enacted the Drug Price Competition and Patent Term Restoration Act, Pub.L. No. 98-417, 98 Stat. 1585 (1984) (the “Hatch-Waxman Amendments”), amending the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. §§ 301-392. The…
2Cases cited7 opinions
- Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 1984
- Eli Lilly & Co. v. Medtronic, Inc.Supreme Court of the United States · 1990
- Glaxo Operations Uk Limited v. Donald J. Quigg, Assistant Secretary of Commerce and Commissioner of Patents and TrademarksCourt of Appeals for the Federal Circuit · 1990
- Comite Pro Rescate De La Salud, Etc. v. Puerto Rico Aqueduct and Sewer Authority, Etc.Court of Appeals for the First Circuit · 1989
- National Ass'n of Casualty & Surety Agents v. Board of Governors of the Federal Reserve SystemCourt of Appeals for the D.C. Circuit · 1988
2 more not listed; retrieve them via the Exa API.
3Cited by83 opinions
- Mylan Pharmaceuticals, Inc. v. ShalalaDistrict Court, District of Columbia · 2000
- Rhone-Poulenc Rorer Pharmaceuticals, Inc. v. Marion Merrell Dow, Inc.Court of Appeals for the Eighth Circuit · 1996
- State v. ThomasSupreme Court of New Jersey · 2001
- Goldstein v. Securities & Exchange CommissionCourt of Appeals for the D.C. Circuit · 2006
- Mylan Laboratories, Inc. v. Tommy G. Thompson, Secretary, United States Department of Health and Human ServicesCourt of Appeals for the D.C. Circuit · 2005
78 more not listed; retrieve them via the Exa API.